BioBridgeX
Log inCompare quotes
Indication

Infectious Disease CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing an infectious disease program means buying BSL-2/BSL-3 lab access, validated pathogen panels, and animal challenge models you cannot run in-house. CROs cover MIC and time-kill assays, antiviral and antibacterial efficacy, resistance studies, and PK/PD, while CDMOs handle biologics, vaccines, and sterile fill-finish. On BioBridgeX, buyers source and compare vetted suppliers and contract directly with their chosen supplier, free for buyers, with a flat 2% supplier fee.

Infectious Disease CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Infectious Disease CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does an Infectious Disease program need?

Infectious disease is one of the few areas where your drug has a living, mutating opponent, and that shapes almost every piece of the outsourcing scope. Discovery work starts with in vitro potency against the pathogen itself: MIC and MBC for antibacterials, plaque-reduction and yield-reduction assays for antivirals, and EC50 panels run across a spread of clinical isolates rather than a single lab strain. The single most useful question to ask a supplier early is which pathogens they actually hold, under what biosafety level, and whether their strain panel reflects current resistance patterns or a collection that stopped being representative years ago.

From there the work moves into the parts most sponsors cannot run themselves. Resistance characterization (serial passage to select resistant mutants, frequency-of-resistance measurement, whole-genome sequencing to map the mechanism) tells you how durable your molecule is. Time-kill kinetics and the hollow-fiber infection model bridge potency to dosing by showing whether the drug is concentration- or time-dependent. Then come the in vivo efficacy models: neutropenic mouse thigh and lung infection for bacteria, sepsis and bacteremia models, and respiratory or systemic challenge models for viral and fungal programs. A meaningful share of this lives at BSL-3 (think influenza, TB, certain BSL-3 select agents), and not every CRO is built or licensed for it.

Two things separate infectious disease from most other therapeutic areas, and a good supplier will raise them before you do. PK/PD integration matters more here than almost anywhere else: regulators expect a defined PK/PD index and target (fAUC/MIC, %T>MIC, or Cmax/MIC) tied back to the animal models, so the group running your efficacy studies should speak that language. And on the biologics and vaccine side, the CDMO scope is real, with cell-line and viral-vector manufacturing, adjuvant formulation, potency and neutralizing-antibody assays, and sterile fill-finish, all under the cold-chain and sterility constraints these products demand.

How do you choose a CRO for Infectious Disease?

The deciding factor in infectious disease is rarely price, it is whether the supplier genuinely has the pathogen, the biosafety containment, and the validated model your specific program needs. A CRO with a beautiful BSL-2 bacterial efficacy operation is the wrong choice for a respiratory virus that demands BSL-3 challenge work, and a strain collection that does not include current resistant isolates will flatter a weak molecule. Scope two or three suppliers against the same written protocol and work through the checklist below before you commit.

  • Therapeutic-area and pathogen experience: confirm they have run programs against your specific organism class (Gram-negative, mycobacteria, respiratory virus, fungus) and ask for relevant, recent work, not a generic capability slide.
  • Strain panels and patient relevance: check that their isolate collection reflects current resistance, including reference and clinical strains and the relevant ATCC or CLSI panels, plus any drug-resistant lineages your indication targets.
  • Biosafety containment and licensing: verify the actual biosafety level (BSL-2 vs BSL-3) for both lab and animal work, select-agent registration where it applies, and that containment is licensed for your pathogen rather than aspirational.
  • Regulatory and quality track record: ask whether IND-enabling studies run under GLP, how their MIC and susceptibility methods map to CLSI or EUCAST breakpoints, and whether their PK/PD packages have supported FDA or EMA submissions.
  • Data quality and method validation: look for documented assay validation, QC controls on every plate, isolate provenance and authentication, and raw data you can trace, since an unvalidated potency assay poisons every decision downstream.
  • PK/PD and translational depth: confirm they can connect in vitro potency, time-kill, and hollow-fiber data to a defined PK/PD index and animal efficacy, which is what regulators expect for an anti-infective dose rationale.
  • Capacity and realistic lead time: BSL-3 suites and challenge-model slots are genuinely scarce, so confirm current queue and a realistic start date rather than assuming availability.

Frequently asked questions

What does an infectious disease CRO actually do?
Most infectious disease CROs cover a chain that runs from in vitro potency through in vivo proof of efficacy. On the bench that means MIC, MBC, and time-kill assays for antibacterials, plaque-reduction and EC50 panels for antivirals, and broth or agar susceptibility testing across clinical isolates. Beyond potency they characterize resistance (serial passage, frequency of resistance, sequencing the mutant), run hollow-fiber and PK/PD studies, and execute animal models such as the neutropenic mouse thigh, lung infection, and sepsis models, plus respiratory or systemic challenge studies for viral and fungal programs. Many also offer GLP toxicology to support an IND. Suppliers differ most in biosafety level and the breadth and currency of their strain collection, so confirm those two things before scope.
Do I need a BSL-3 lab, and how do I know if a CRO has one?
It depends entirely on your pathogen. Many bacterial and fungal programs run comfortably at BSL-2, but agents like Mycobacterium tuberculosis, several respiratory viruses including influenza subtypes, and certain select agents require BSL-3 containment for both lab and animal work. BSL-3 capacity is scarce and expensive, which is exactly why you should verify it rather than assume it. Ask the supplier for their biosafety level by activity (in vitro versus in vivo can differ), whether the containment is licensed for your specific organism, and whether they hold select-agent registration if your pathogen is on that list. A CRO that cannot answer crisply probably does not have it.
How do CROs test for antimicrobial or antiviral resistance?
Resistance work answers how durable your molecule is against an opponent that adapts. The common approaches are serial-passage selection (growing the pathogen under increasing drug pressure to force resistant mutants), frequency-of-resistance measurement (how often spontaneous resistance arises at a given concentration), and checkerboard or combination studies to find synergy. Once a resistant isolate emerges, whole-genome sequencing maps the mechanism back to a mutation or efflux pathway. For antivirals the same logic applies through passage and deep sequencing of the viral population. Strong suppliers run this against clinically relevant strains, not just a lab-adapted reference, because resistance that only shows up in an artificial strain tells you very little about the clinic.
Can one supplier handle both the CRO testing and the CDMO manufacturing for a vaccine or biologic?
Sometimes, but it is worth scoping deliberately rather than assuming. Anti-infective small molecules usually split cleanly: a CRO for efficacy and PK/PD, a separate CDMO for API and drug product. Vaccines and biologics blur the line, since the same group running potency, neutralizing-antibody, and immunogenicity assays may also offer cell-line development, viral-vector or protein manufacturing, adjuvant formulation, and sterile fill-finish. A few larger providers cover the full span. The practical issue for buyers is usually finding and comparing several specialists, which is the gap BioBridgeX closes: you can compare quotes from multiple vetted suppliers in one place and contract directly with the ones you choose.
What is the PK/PD index and why do infectious disease programs care so much about it?
The PK/PD index links how much drug exposure you achieve to how much pathogen killing you get, and it is central to anti-infective dosing. The three standard indices are fAUC/MIC, the percentage of the dosing interval that free drug stays above the MIC (%fT>MIC), and Cmax/MIC, and most drugs are driven by one of them. Establishing which index governs your molecule, and the target value needed for efficacy, is something regulators expect you to show with animal models and hollow-fiber data before you set a human dose. That is why the CRO running your efficacy studies should be fluent in PK/PD, not just able to report an MIC. It directly shapes your dose, your dosing frequency, and your clinical design.
How much does infectious disease preclinical testing cost and how long does it take?
There is no honest single figure, because the range runs from a quick in vitro MIC panel measured in weeks to a full IND-enabling package with BSL-3 challenge models and GLP toxicology measured in many months. The biggest cost and timeline drivers are biosafety level (BSL-3 work carries a real premium and limited slot availability), the number and complexity of animal models, and whether resistance and PK/PD studies are in scope. Comparing two or three suppliers against an identical written protocol is the only way to get prices that actually mean the same thing, since one quote may bundle assay development and confirmation that another leaves out. Staging the work as milestones with go/no-go gates keeps both spend and schedule under control.

Source Infectious Disease work with one contract

Compare transparent quotes from qualified Infectious Disease CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes